Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL45542 | 1.00 | HSD17B3 (0.42) | HSD17B3ALOX5CES2CES1ESR1 | |
| SCHEMBL45044 | 0.83 | HDAC3 (0.43) | CES2CES1ESR1ALDH1A1TDP1 | |
| SCHEMBL1075702 | 0.83 | HDAC3 (0.43) | CES2CES1ESR1ALDH1A1TDP1 | |
| Phenol SCHEMBL28106942 | 0.77 | ALDH1A1 (0.52) | HSD17B3ALOX5CES2CES1ESR1 | |
| Phenol SCHEMBL28594893 | 0.76 | HDAC3 (0.54) | HSD17B3ALOX5CES2CES1ESR1 | |
| Phenol SCHEMBL2369589 | 0.75 | HDAC3 (0.59) | HSD17B3ALOX5CES2CES1ESR1 | |
| Phenol SCHEMBL28578978 | 0.75 | TDP1 (0.55) | HSD17B3ALOX5CES2CES1ESR1 | |
| Phenol SCHEMBL5934375 | 0.74 | TDP1 (0.61) | ALOX5CES2CES1ESR1L3MBTL1 | |
| Phenol SCHEMBL28833788 | 0.74 | TDP1 (0.61) | ALOX5CES2CES1ESR1L3MBTL1 | |
| Phenol SCHEMBL28682879 | 0.74 | CES1 (0.55) | HSD17B3ALOX5CES2CES1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4252754-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | Shanghai Juncell Therapeutics Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-115160295-A | Amide compounds as kinase inhibitors | 转化药物开发有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-112513019-B | HCV inhibitor disodium salt crystal form C and preparation method thereof | 广东东阳光药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-115006392-A | Composition of PI5P 4K-beta inhibitor and application thereof | 深圳晶泰科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-109069507-B | Use of pimobendan to reduce heart size and/or delay onset of clinical symptoms | 勃林格殷格翰维特梅迪卡有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112424172-B | Salts of HCV inhibitors and process for preparing the same | 广东东阳光药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114829349-A | Condensed thiophene derivatives as Hypoxia Inducible Factor (HIF) inhibitors | 默克专利股份公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110099906-B | Amide compounds as kinase inhibitors | 转化药物开发有限责任公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114746110-A | Vaccine and immunoglobulin targeting African swine fever virus, and methods of making and using the same | IGY免疫技术和生命科学公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2005033056-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005021547-A2 | HETEROCYCLIC CANNABINOID CB2 RECEPTOR ANTAGONISTS | PHARMAXIS PTY LTD. (AU) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005000217-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | MERCK & CO., INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20030021773-A1 | Arginine mimetics as factor Xa inhibitors | WILEX AG (DE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | CTSA, GZMB, PRF1 | HSD17B3 4561/4885ALOX5 291/4885CES2 2174/4885 |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | GPR119, GIPR, FABP6 | HSD17B3 663/4885ALOX5 592/4885CES2 324/4885 |
| US-20030021773-A1 | Arginine mimetics as factor Xa inhibitors | ARGLU1, F11, ARG1 | HSD17B3 4513/4885ALOX5 2388/4885CES2 4120/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | HSD17B3 4440/4885ALOX5 2845/4885CES2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.